Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements examine uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://heraclitusy008nbv7.blogsuperapp.com/profile